PTC/SBS0CF6 67 bits
Approved for the Brody's B7/31/2513 - OME 6651-6031
D-S-Patent and Trademan Office; U.S. DEPARTMENT OF COMMERCE

Under the Planamore Pedacison Acrold 1995, on persons are conceed to respect to a collection of information valers is contains a varid Child contains REQUEST FOR CONTINUED EXAMINATION/RCE)TRANSMITTAL (Submitted Only via EFS-Web) Application Filling Docket Number Air 2004-03-02 10/793 403 09792909,5824 1795 Number Oate (if applicable) First Named Examiner Yuzuru FUKUSHIMA Reymond ALEJANDRO inventor Name This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8. 1995, or to any design explication. The instruction Sheet for this form is located at WWW.USPTG.GGV SUBMISSION REQUIRED LINDER 37 CFR 1 114 Note, if the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. Consider the arguments in the Appeal Brief or Reply Brief previously filed on C Other Enclosed Amendment/Reply Information Disclosure Statement (IDS) Affidavit(s)/ Declaration(s) M Other MISCELLANGOUS Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) C Other FEES The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge any undergayment of fees, or credit any overpayments to Deposit Account No. 103140 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED Patent Practitioner Signature

Applicant Signature

Doc code: RCEX

Doc description. Request for Continues Examination (RCE)

FT CREATROFF S. (371%)
Approved for now through 07011 2018. ONE DECLINED
U.S. Faters and Travernark Office, U.S. DEPARTMENT OF CONSISTING.

Observation (Modified In Committee Examination (MCE)

U.S. Pains and Traversian Colon, U.S. DEPARTMENT OF CONSISTANCE UNIVERSAL TRAVERSAL AND ADMINISTRATION AND ADMINISTRATION OF CONSISTANCE OF CONSIST

Signature of Registered U.S, Patent Practitioner			
Signature	2 Had Shop	Date (YYYY-MM-OD)	2009-08-13
Name	G. Harlay Blosser	Registration Number	33650

This collisation of information is required by 37 CFR 1.114. The information is required to obtain or retailing a benefit by the public which is to fife (and by the (DPFTO b) processes) an application. Confidentiality is operand by 35 US 0.1.22 and 37 CFR 1.13 and 1.14 fine collection is estimated to fake 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form any comments on the amount of time you require to complete this form any comments on the amount of time you require to complete this form any confidence of reducing this buttless, should be sent to the Charl Information Officer, U.S. Patent and Trudemark Office, U.S. Department of Commerce, P.O. 8th 1450, Alexendral, W.A. 2313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicided is volunitary; and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not United requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- 1 The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (6 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
 court, registrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
 neodistance.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, by whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filter in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an essued order.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.